Latest Articles
EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic - PR Newswire
EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic PR Newswire
Published: Sept. 16, 2025, 1 p.m.
United States Endometriosis Therapeutics Market Set for Robust - openPR.com
United States Endometriosis Therapeutics Market Set for Robust openPR.com
Published: Sept. 11, 2025, 9:57 a.m.
Real time breakdown of Brainstorm Cell Therapeutics Inc. stock performance - 2025 Analyst Calls & Momentum Based Trading Signals - Newser
Real time breakdown of Brainstorm Cell Therapeutics Inc. stock performance - 2025 Analyst Calls & Momentum Based Trading Signals Newser
Published: Aug. 22, 2025, 6:09 p.m.
Endometriosis-Associated Infertility: Multi-Omics Insights into Pathogenesis and Precision Therapeutics - Frontiers
Endometriosis-Associated Infertility: Multi-Omics Insights into Pathogenesis and Precision Therapeutics Frontiers
Published: Aug. 15, 2025, 1:08 p.m.
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights The Manila Times
Published: Aug. 13, 2025, 8:31 p.m.
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights GlobeNewswire
Published: Aug. 13, 2025, 8:17 p.m.
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics Inc. SEC 10-Q Report TradingView
Published: Aug. 11, 2025, 11:43 a.m.
Lisata Therapeutics Q2 2025: Key Contradictions in ASCEND Trial Insights and Financial Projections - AInvest
Lisata Therapeutics Q2 2025: Key Contradictions in ASCEND Trial Insights and Financial Projections AInvest
Published: Aug. 8, 2025, 7:14 a.m.
Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer - TipRanks
Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer TipRanks
Published: Aug. 7, 2025, 4:18 p.m.
Onconic Therapeutics announced on the 28th that "Nesuparib," a candidate for a double-targeted antic.. - 매일경제
Onconic Therapeutics announced on the 28th that "Nesuparib," a candidate for a double-targeted antic.. 매일경제
Published: July 28, 2025, 6:56 a.m.
Link copied to clipboard!